Non-Myeloablative Bone Marrow Reconstitution With Chemotherapy-Resistant Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional bone marrow transplants, particularly myeloablative ones, cause severe side effects due to the destruction of healthy immune and stem cells, leading to prolonged susceptibility to infections and recovery periods, which can last up to six months.
Innovation Solution
A non-myeloablative bone marrow transplant method using chemotherapeutic-resistant modified cells, such as those expressing ALDH1, is administered with a non-myeloablative dose of a chemotherapeutic agent like cyclophosphamide, allowing engraftment without myeloablation, thereby reducing toxicity and immune suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If myeloablative BMT is performed to replace damaged bone marrow, then bone marrow reconstitution is achieved, but severe side effects occur due to destruction of healthy immune and stem cells
Solution Approach 1:
The patent changes the dosage parameter of chemotherapeutic agents from myeloablative to non-myeloablative levels. Specifically, it uses reduced doses of cyclophosphamide (1-10 mg/kg/day) and fludarabine (0.1-0.5 mg/kg/day) that are sufficient to achieve bone marrow reconstitution without causing complete destruction of healthy cells, thereby reducing severe side effects while maintaining therapeutic effectiveness
Solution Approach 2:
The patent introduces chemotherapeutic-resistant modified cells as intermediaries that carry therapeutic genes (such as HIV resistance genes or other disease-specific therapeutic genes) into the patient's bone marrow. These modified cells serve as vectors that deliver therapeutic functions without requiring extensive myeloablation, thus reducing harm to healthy cells while achieving the desired therapeutic outcome
2Reliability
If high doses of chemotherapy and radiation are used to kill bone marrow cells, then myeloablation is achieved, but patients become susceptible to infections for up to six months
Solution Approach 1:
The patent changes the intensity parameter of the conditioning regimen from high-dose myeloablative to low-dose non-myeloablative chemotherapy. By using reduced doses of agents like cyclophosphamide and fludarabine, the patent achieves sufficient bone marrow suppression and reconstitution without the prolonged immune deficiency that characterizes high-dose regimens, thereby significantly shortening the recovery period from six months to a much shorter duration
Solution Approach 2:
The patent performs preliminary gene modification of stem cells ex vivo before transplantation. The stem cells are transduced with therapeutic genes (such as HIV resistance genes) in advance, so that when they engraft, they immediately provide therapeutic function without requiring extensive myeloablation or prolonged recovery, thus reducing the time patients remain susceptible to infections
3Reliability
If myeloablative chemotherapy is administered to treat bone marrow diseases, then disease treatment is achieved, but acute toxicities and long-term side effects occur
Solution Approach 1:
The patent changes the dose parameter of chemotherapeutic agents from myeloablative to non-myeloablative levels. By using reduced doses of cyclophosphamide (1-10 mg/kg/day) and fludarabine (0.1-0.5 mg/kg/day), the patent maintains disease treatment effectiveness while significantly reducing acute toxicities such as severe nausea, vomiting, and bone marrow suppression, as well as long-term side effects like cataracts, growth retardation, and endocrine problems
Solution Approach 2:
The patent uses chemotherapeutic-resistant modified cells as intermediaries that deliver therapeutic functions directly to the bone marrow. These cells express resistance genes (such as ALDH1) that protect them from chemotherapy damage, allowing the cells to survive and engraft without requiring high-dose myeloablative chemotherapy, thereby reducing both acute and long-term toxicities while maintaining treatment effectiveness
Data Source
AI summary
The disclosure relates generally to methods and compositions for performing bone marrow transplants using a non-myeloablative chemotherapeutic agent and chemotherapeutic-resistant cells. Using the methods and compositions described herein, a patient's bone marrow may be reconstituted and the patient avoids adverse side effects, including myeloablation and/or an impaired immune system.